Observational studyOncology reports2020
RP11‑619L19.2 promotes colon cancer development by regulating the miR‑1271‑5p/CD164 axis.
Observational study in Oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Machine learning-based survival prediction in colorectal cancer combining clinical and biological features.Oncotarget · 2025Article
- CircUSP10 promotes liver cancer progression by regulating miR-211-5p/TCF12/EMT signaling pathway.Heliyon · 2023Article
- In silico analysis to identify miR-1271-5p/PLCB4 (phospholipase C Beta 4) axis mediated oxaliplatin resistance in metastatic colorectal cancer.Scientific reports · 2023Article
- FAM201A Promotes Cervical Cancer Progression and Metastasis through miR-1271-5p/Flotillin-1 Axis Targeting-Induced Wnt/Journal of oncology · 2022Article
- SUMOylation of IGF2BP2 promotes vasculogenic mimicry of glioma via regulating OIP5-AS1/miR-495-3p axis.International journal of biological sciences · 2021Article
- Constructing the ceRNA Regulatory Network and Combining Immune Cells to Evaluate Prognosis of Colon Cancer Patients.Frontiers in cell and developmental biology · 2021Article
- Long noncoding RNAs: functions and mechanisms in colon cancer.Molecular cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colon cancer (CC) is one of the leading causes of cancer‑related mortality in China and western countries. Several studies have demonstrated that long non‑coding RNAs (lncRNAs) play critical roles in cancer development. However, the function of lncRNA RP11‑619L19.2 in colon cancer remains unclear. The aim of the present study was to investigate the expression pattern, function and underlying mechanism of action of RP11‑619L19.2 in CC development and metastasis. RP11‑619L19.2 was found to be highly expressed in CC tissues and cell lines, and it was associated with advanced TNM stage and lymph node metastasis. Furthermore, knockdown of RP11‑619L19.2 inhibited CC cell proliferation, migration, invasion and epithelial‑to‑mesenchymal transition (EMT). It was also observed that RP11‑619L19.2 was reciprocally repressed by miR‑1271‑5p. Of note, miR‑1271‑5p negatively regulated CD164 expression by directly targeting the 3'‑untranslated region of CD164. Overexpression of CD164 reversed the antimetastatic activity of RP11‑619L19.2 knockdown in CC cells. Mechanistically, it was demonstrated that lncRNA RP11‑619L19.2 played an oncogenic role and promoted CC development and metastasis by regulating the miR‑1271‑5p/CD164 axis and EMT. In conclusion, the findings of the present study indicated that RP11‑619L19.2 regulates CD164 expression and EMT by sponging miR‑1271‑5p, which may provide novel targets for lncRNA‑directed diagnosis and therapy for patients with CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.